Rett Syndrome Research Trust Launches the MECP2 Editing Consortium With Goal to Advance Programs to Clinical Trials

The Rett Syndrome Research Trust (RSRT) has taken a significant stride in the pursuit of innovative genetic medicines for Rett syndrome by establishing the MECP2 Editing Consortium. Mutations in MECP2 cause Rett syndrome, a debilitating neurological disorder that causes a lifetime of...
Source: PRWeb: Medical Pharmaceuticals - Category: Pharmaceuticals Source Type: news